Two stage hepatectomy (TSH) versus ALPPS for initially unresectable colorectal liver metastases: A systematic review and meta-analysis

医学 肝切除术 围手术期 置信区间 相对风险 荟萃分析 阶段(地层学) 内科学 胃肠病学 外科 切除术 生物 古生物学
作者
Tamara Díaz Vico,Pablo Granero Castro,Laura Alcover Navarro,A Suárez Sánchez,Luka Mihic-Góngora,Eva Montalvá,Javier Maupoey,Nuria Truán,Ignacio González-Pinto Arrillaga,J E Granero Trancón
出处
期刊:Ejso [Elsevier BV]
卷期号:49 (3): 550-559 被引量:6
标识
DOI:10.1016/j.ejso.2022.11.010
摘要

Background Although numerous comparisons between conventional Two Stage Hepatectomy (TSH) and Associating Liver Partition and Portal Vein Ligation for staged hepatectomy (ALPPS) have been reported, the heterogeneity of malignancies previously compared represents an important source of selection bias. This systematic review and meta-analysis aimed to compare perioperative and oncological outcomes between TSH and ALPPS to treat patients with initially unresectable colorectal liver metastases (CRLM). Methods Main electronic databases were searched using medical subject headings for CRLM surgically treated with TSH or ALPPS. Patients treated for primary or secondary liver malignancies other than CRLM were excluded. Results A total of 335 patients from 5 studies were included. Postoperative major complications were higher in the ALPPS group (relative risk [RR] 1.46, 95% confidence interval [CI] 1.04–2.06, I2 = 0%), while no differences were observed in terms of perioperative mortality (RR 1.53, 95% CI 0.64–3.62, I2 = 0%). ALPPS was associated with higher completion of hepatectomy rates (RR 1.32, 95% CI 1.09–1.61, I2 = 85%), as well as R0 resection rates (RR 1.61, 95% CI 1.13–2.30, I2 = 40%). Nevertheless, no significant differences were achieved between groups in terms of overall survival (OS) (RR 0.93, 95% CI 0.68–1.27, I2 = 52%) and disease-free survival (DFS) (RR 1.08, 95% CI 0.47–2.49, I2 = 54%), respectively. Conclusion ALPPS and TSH to treat CRLM seem to have comparable operative risks in terms of mortality rates. No definitive conclusions regarding OS and DFS can be drawn from the results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杜兰特工队完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助150
1秒前
2秒前
龚宇发布了新的文献求助10
3秒前
科研通AI6应助郑涵采纳,获得30
3秒前
3秒前
研友_VZG7GZ应助对对采纳,获得10
3秒前
4秒前
5秒前
火星上初曼完成签到,获得积分10
5秒前
6秒前
6秒前
Song发布了新的文献求助10
7秒前
7秒前
大胆的忆寒完成签到,获得积分20
8秒前
8秒前
二三发布了新的文献求助10
8秒前
9秒前
酷波er应助17采纳,获得10
9秒前
Akim应助科研混子采纳,获得10
9秒前
9秒前
mispring发布了新的文献求助10
9秒前
身强力壮运气好完成签到,获得积分10
10秒前
11秒前
祺王862完成签到,获得积分10
11秒前
13秒前
14秒前
14秒前
15秒前
15秒前
小康找文献完成签到,获得积分10
15秒前
香蕉觅云应助大胆的忆寒采纳,获得10
16秒前
科目三应助Tracy麦子采纳,获得10
17秒前
zh发布了新的文献求助10
18秒前
19秒前
大个应助二三采纳,获得10
20秒前
21秒前
21秒前
fff发布了新的文献求助10
21秒前
对对发布了新的文献求助10
22秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
LRZ Gitlab附件(3D Matching of TerraSAR-X Derived Ground Control Points to Mobile Mapping Data 附件) 2000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5134322
求助须知:如何正确求助?哪些是违规求助? 4335087
关于积分的说明 13505951
捐赠科研通 4172482
什么是DOI,文献DOI怎么找? 2287697
邀请新用户注册赠送积分活动 1288658
关于科研通互助平台的介绍 1229444